Publicaciones en colaboración con investigadores/as de Klinikum der Universität München (7)

2024

  1. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

    Journal of Clinical Oncology, Vol. 42, Núm. 9, pp. 987-993

  2. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆

    Annals of Oncology, Vol. 35, Núm. 2, pp. 159-182

  3. Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer

    European Journal of Cancer, Vol. 199

  4. Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer

    Journal of Clinical Oncology, Vol. 42, Núm. 9, pp. 994-1000

  5. Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)

    ESMO Open, Vol. 9, Núm. 3

2007

  1. Venous thromboembolism (VTE) in Europe - The number of VTE events and associated morbidity and mortality

    Thrombosis and Haemostasis, Vol. 98, Núm. 4, pp. 756-764

1993

  1. Comparison of the effects of volume resuscitation with Dextran 60 vs. Ringer's lactate on central hemodynamics, regional blood flow, pulmonary function, and blood composition during hyperdynamic endotoxemia

    Circulatory Shock, Vol. 39, Núm. 2, pp. 89-99